IDL DIAGNOSTICS CHANGES ACCOUNTING PRINCIPLES TO IFRS STARTING FROM THE THIRD QUARTER REPORTING

IDL Diagnostics announces that the company's board has decided to change the accounting principles from the Swedish K3 regulations to the International Financial Reporting Standards (IFRS) starting from the reporting of the third quarter on 12 November 2025.

The main rule in IFRS is that all standards are applied retroactively when establishing the opening balance under IFRS. The transition date to IFRS has been set to 1 January 2024. The primary accounting areas affected by the transition are increased financial information in the financial reports, changed principles for accounting of lease agreements, and that amortization of goodwill will no longer take place. In 2024, goodwill amortizations related to acquisitions amounted to SEK 40 million, and in the first half of 2025, these amortizations amounted to SEK 20 million. As goodwill amortization will no longer be performed under IFRS, this means an improvement in operating profit by the corresponding amount.

"The purpose of changing to IFRS is to increase transparency and improve the quality of financial information, thereby making it easier for investors and market participants to make informed decisions. We see this as a crucial step in preparing the company for our continued growth journey and future opportunities," says Anders Hultman, CEO of IDL Diagnostics.

Contacts

Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: **anders.hultman@idldiagnostics.com**

About IDL Diagnostics

IDL Diagnostics AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, IDL Diagnostics uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. IDL Diagnostics' product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. IDL Diagnostics (IDLDX) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; **www.idldiagnostics.com**

Attachments

IDL Diagnostics changes accounting principles to IFRS starting from the third quarter reporting